Head-to-head evidence
certolizumab pegol vs infliximab-dyyb (Zymfentra)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT00308581 · Phase 3 · completed
The pre-specified PRIMARY outcome (induction-phase response) was measured in a single arm with no randomization, no control group, and no comparator, meeting the 'weak' test for an uncontrolled design regardless of the favorable-looking 62% rate; the trial's only randomized, double-blind, controlled comparison (Q4W vs Q2W) was a secondary/non-hard endpoint that was also non-significant, which would only support 'moderate' at best and cannot upgrade the uncontrolled primary endpoint.
infliximab-dyyb (Zymfentra)
Marketed by Celltrion
NCT03945019 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.
Next expected readout: December 2026 · NCT06064864 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: certolizumab pegol's landscape · infliximab-dyyb (Zymfentra)'s landscape